Published in Nature on August 02, 2017
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
The Genotype-Tissue Expression (GTEx) project. Nat Genet (2013) 10.77
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol (2013) 4.88
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med (2016) 4.31
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 3.51
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med (2015) 2.88
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
The landscape of kinase fusions in cancer. Nat Commun (2014) 2.48
Robust enumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 2.30
GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 2.21
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst (2015) 1.70
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg (2009) 1.40
Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer (2015) 1.24
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer (2008) 1.16
The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med (2013) 1.13
Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet (2016) 1.12
Metastasis as an evolutionary process. Science (2016) 1.11
Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front Genet (2015) 1.01
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res (2015) 0.97
Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Hum Pathol (2014) 0.92
Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer (2014) 0.85
MAGI: visualization and collaborative annotation of genomic aberrations. Nat Methods (2015) 0.83
The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med (2014) 0.78